In a phase I clinical trial (NCT02410733), 119 melanoma patients were vaccinated with an RNA-LPX vaccine encoding the four melanoma TAAs MAGE-A3, transmembrane phosphatase with tensin homology (TPTE), NY-ESO-1 and tyrosinase [40, 41]. The gene discussed is TPTE; the disease is melanoma.